Short answer
Xenon Pharmaceuticals Inc. (XENE) filed an 8-K current report with the SEC on April 13, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Inducement Plan capacity increased 275,000 shares, from 900,000 to 1,175,000.
Xenon Pharmaceuticals Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Inducement Plan capacity increased 275,000 shares, from 900,000 to 1,175,000
- Additional equity reserved exclusively for new or rehired employees
- Potential shareholder dilution from future options, RSUs, and performance awards
- No shareholder approval required under Nasdaq Listing Rule 5635(c)(4)
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Xenon Pharmaceuticals Inc. 8-K filings
Get the next XENE 8-K as it lands
Follow XENE for push alerts, or ask the research agent what this filing means.